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A functional variant in the UBE2B gene
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Abstract
Background: A variety of genetic variants lead to abnormal human spermatogenesis. The ubiquitin-conjugating
enzyme E2B (UBE2B) plays a significant role in spermatogenesis as Ube2b-knockout male mice are infertile.
Methods: In this study, we sequenced the exon and promoter region of UBE2B in 776 patients diagnosed with
idiopathic azoospermia (IA) and 709 proven fertile men to examine whether UBE2B is involved in the pathogenesis
of IA.
Results: In the exon region, two novel synonymous variants were detected in the patient group. In the promoter
region, four known variants and four novel variants were identified in the patient group. Of the novel variants in
the promoter region, three were located at the binding site of specificity protein 1 (SP1) transcription factor
analyzed by TRANSFAC software. Luciferase assays demonstrated that one heterozygous variant (Chr5.133706925
A > G) inhibited the transcriptional regulation activity of SP1.
Conclusions: A novel variant (Chr5.133706925 A > G) residing in the UBE2B gene promoter region confers a high
risk for IA in a Chinese population. These results support a role for UBE2B in the pathogenesis of IA.
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Background
Approximately 15 % of couples at child-bearing age are
infertile [1–3]. Idiopathic azoospermia (IA), one of the
most severe forms of male infertility, affects up to 1 % of
all adult men in the general population [4]. Although the
genetic causes of IA remain largely unknown in humans,
familial case reports and experimental studies in mice
have demonstrated that many variants in different genes
can result in spermatogenesis defects [5–7]. Recent studies
also indicate that genetic variants in the promoter region
are associated with IA risk as well [8–10].
The ubiquitin-conjugating enzyme E2B (UBE2B), also
known as Rad6b or Hr6b, is located at chr5:133706870–
133727799. UBE2B belongs to the Ubiquitin Proteasome
System, which mediates H2A and H2B ubiquitylation
and function during transcription [11]. Previous studies
have shown that the variants of UBE2B are associated
with male infertility in humans [12–15]. Other evidence
from experimental studies has also shown that Ube2b
knockout male mice are infertile with low numbers of
predominantly abnormal spermatozoa, abnormal sperm-
atid nuclear condensation, sperm periaxonemal anomal-
ies, damaged synaptonemal complex structure and/or
increased cross-over frequency [16, 17].
Because the UBE2B gene is essential for normal
spermatogenesis [12–14, 18], the genetic variants that
affect UBE2B expression may be involved in the etiology
of human IA. Therefore, the objective of this study was
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on July 18th, 2009, initiated on August 1st, 2009 and
terminated on December 1st, 2014.
Patient samples
A total of 1,880 azoospermic patients were recruited for
this study from the Peking University Shenzhen Hos-
pital and the Center of Reproductive Medicine, Tongji
Medical College, Huazhong University of Science and
Technology. Among them, 776 patients fulfilled the cri-
teria for IA diagnosis as follows: (1) no sperm detected
in the pellets of semen samples at three different occa-
sions, (2) no obstruction, inflammation and injury of the
reproductive system or pelvic cavity, (3) no endocrino-
logical defect, and (4) no karyotypic abnormality and Y
chromosome microdeletion. A total of 709 fertile men
from the Center of Physical Examination, Peking Uni-
versity Shenzhen Hospital were recruited as controls:
they had fathered at least one child without assisted re-
productive techniques such as IVF, ICSI and IMSI. After
a panel re-sequencing study and quality control steps,
776 patients aged 24–46 years (average 30.6) and 709
fertile men aged 29–51 years (average 35.6) were avail-
able for further analysis. Informed written consent was
obtained from each subject.
Panel re-sequencing study
Five micrograms of genomic DNA isolated from periph-
eral blood samples were sent to the Beijing Genomics
Institute at Shenzhen for exome capture and sequen-
cing. The capture procedure was performed in solution
with a NimbleGen custom array (Roche NimbleGen,
Madison, WI, USA) that is capable of enriching the ex-
onic sequences of 654 infertility- or subfertility-related
genes [19]. Most of these genes were reviewed by Mat-
zuk and Lamb [5]. Moreover, we also selected other
genes that were shown to cause male reproductive de-
fects in mouse models from studies published between
November, 2008 and December, 2010. A panel re-
sequencing study was performed on the Illumina plat-
form with pair-end 90 bp reads.
Fastq sequence files were aligned against the human
reference genome (NCBI build 37.1, hg19) with the
SOAPaligner software (2.21). Duplicated pair-end reads
were removed from the merged data sets. Single nucleo-
tide variants that were different from the hg19 reference
genome were filtered out if they met any of the following
criteria: Phred-like quality score ≤ 20, overall depth ≤ 8×,
estimated copy number ≥ 2 or the genomic distance be-
tween two adjacent variants < 5 bp. In addition, the quality
score of both the major and minor allele at heterozygous
locus should be at least 20. Variants were then annotated
using an in-house functional prediction tool and were
compared to dbSNP135 and 1000 Genomes databases
(as of August, 2010).
Polymerase chain reaction (PCR) analysis of UBE2B
promoter
Four sets of PCR primers (Table 1) were developed and opti-
mized to amplify the promoter and 5’ UTR region 2551 bp
upstream of the UBE2B coding region from HeLa cells by
PCR with the following primers: promoter 1, CCCAGGAC
AAAGATGAAC (forward), AGAATCGCTTGAGACGAG
(reverse); promoter 2, CTTCAACTTCCTCGTCTCA (for-
ward), CACCGTCCTTCCCTCTAT (reverse); promoter 3,
AGAGGGAAGGACGGTGAC (forward), CGGGTTTAAG
AGGGTGAG (reverse); and promoter 4, CCTCTTGGG
TAATGTTGTC (forward), CATCTAGGCGAAGGTGAA
(reverse).
Forward and reverse amplification primers were also used
as sequencing primers. Sequencing was conducted on an
ABI 3730 DNA analyzer. Variants were then annotated
using an in-house functional prediction tool and were com-
pared to dbSNP135 and 1000 Genomes databases (as of
August, 2010).
Plasmids construction
The wild type (WT) and mutant UBE2B promoter bearing
one of the identified variants (Chr5.133706771 T >A,
Chr5.133706876 T >G, Chr5.133706925 A >G) were amp-
lified by PCR with the primers 5'-CGGGGTACCAGGGGC
AAGGCTGAGGCAATGTT -3' (forward) and 5'-CTAGC
TAGCAGGGGCGGGCGGATAATGTCTGAT -3' (reverse)
from the patient genome. The PCR products were subcloned
into a psiCHECK™-2 vector (C8021, Promega, Madison, WI)
with KpnI/NheI sites. All clones were verified by DNA
sequencing.
Luciferase assay
HeLa, 293FT and TM4 cells (ATCC, Manassas, VA, USA)
were cultured in Dulbecco’s Modified Eagle’s Medium (Gibco
BRL, Gaithersburg, MD, USA) supplemented with 10 % fetal
bovine serum, 100 U/mL penicillin and 100 μg/mL strepto-
mycin at 37 °C, 95 % humidity and 5 % CO2. Cells were
seeded in 24-well tissue culture plates 24 h prior to transfec-
tion. Transfection was performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Equivalent amounts (500 ng) of pCMV-
SP1 (OriGene, Rockville, MD, USA), pCMV empty vector
were cotransfected with wild type (WT) or mutant UBE2B
promoter (Chr5.133706771 T>A, Chr5.133706876 T>G,
Chr5.133706925 A>G) plasmids (250 ng), respectively. Cells
were harvested 36 h after transfection and assayed for firefly
and Renilla luciferase expression using the Dual Luciferase
Reporter Assay System (Promega). Renilla luciferase activities
were normalized to firefly luciferase activity.
Histopathology
Testicular tissues from patients with azoospermia were
collected and immediately stored at 4 % paraformaldehyde
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solution. The tissues were sent to the pathology depart-
ment for sections. Slides were stained with hematoxylin
and eosin and then examined using light microscopy.
Statistical analysis
Data were expressed as the mean ± SD. The Student’s t-
test with Bonferroni correction was used to compare
the difference in mean between the variants and WT.
P < 0.05 was considered statistically significant.
Results
Identification of UBE2B variants in patients with IA
To examine whether UBE2B genetic defects were asso-
ciated with IA, we screened for UBE2B exonic variants
in 776 IA patients and 709 men with proven fertility
using the massively parallel sequencing technology. As
shown in Table 1, two synonymous variants were de-
tected in the UBE2B exon region. These two variants
were not reported as genetic polymorphisms in the pub-
lic database dbSNP135 or in the 1000 Genome Project
dataset. However, no missense variants were identified
in our study.
To examine whether UBE2B promoter variants were
associated with IA, we further screened for UBE2B pro-
moter variants by PCR and Sanger sequencing (Fig. 1).
Sequence analysis of the UBE2B promoter region in
776 IA patients and 709 men with proven fertility re-
vealed 8 variants (Table 2). As shown in Table 2, four
variants had not been reported in either the dbSNP135
database or the 1000 Genome Project dataset and were
found to be absent in the normal controls. Further ana-
lysis by TRANSFAC software showed that three of
these variants (Chr5.133706771 T >A, Chr5.133706876 T >
G, and Chr5.133706925 A >G) were located at the binding
site of the SP1 transcription factor. We hypothesized
that these three variants may affect the DNA-binding
ability of SP1 to the UBE2B promoter, thus modifying
UBE2B expression. The following study was focused on
Fig. 1 Eight variants of the UBE2B promoter in patients with IA. Chromatogram traces from Sanger sequencing showing the variants. Ref:
reference sequences








1 133705424 G > A 4 0 rs191553312
2 133706326 A > G 3 6 rs36087117
3 133706612 C > T 12 15 rs1379247
4 133706626 T > C 3 0 rs188750978
5 133706771 T > A 1 0
6 133706876 T > G 1 0
7 133706925 A > G 32 0
8 133706996 T > G 1 0








1 133712363 A > G 1 0 Synonymous
variant
2 133724047 C > A 0 2 Synonymous
variant
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these three variants. In particular, one of these three
variant (Chr5. 133706925 A > G) was identified in 32
patients. All of the 32 patients were heterozygous
variants.
The other three patient-specific variants (Chr5.133705
424 G >A, Chr5133706626 T >C. Chr5. 133706996 T >G)
were not in a regulatory sequence analyzed by TRANSFAC
software. Alignment of the UBE2B promoter sequence to
its orthologs in different species showed that five patient-
specific variants (Chr5.133705424 G >A, Chr5133706626
T >C, Chr5.133706771 T >A, Chr5.133706925 A >G and
Chr5. 133706996 T >G) were not conserved (Fig. 2). Only
one patient-specific variant (Chr5.133706876 T >G) was
conserved (Fig. 2).The subjects with variants listed in
Table 2 did not carry mutations in the other assayed genes.
SP1 failed to activate the UBE2B Chr5.133706925 A > G
promoter
To evaluate whether the identified three variants affect the
role of SP1 in UBE2B promoter activation, luciferase re-
porter constructs containing the UBE2B promoter with
these three variants were tested in HeLa, 293FT and TM4
cell lines. The results showed that SP1 significantly in-
creased UBE2B promoter WT, Chr5.133706771 T >A,
Chr5.133706876 T >G, but not Chr5.133706925 A >G in
comparison to the empty vector (Fig. 3).
Histological analysis
A patient biopsy (No. 188) with UBE2B Chr5.133706925
A > G confirmed the diagnosis of non-obstructive azoo-
spermia. Moreover, we found that spermatogenic cells
were significantly reduced in contorted seminiferous
tubules (Fig. 4a, b).
Discussion
Previous studies suggested that azoospermia may result
from chromosomal aberrations, microdeletions of the Y
chromosome, or single gene variants [20–22]. However,
the underlying genes and molecular mechanisms are not
well identified.
The UBE2B gene is essential for normal spermatogen-
esis, and defects in this gene will lead to spermatogenic
failure. Matzuk's group found that UBE2B variants exist
in oligozoospermic patients, but they did not examine
the correlation between UBE2B and IA. In this study, we
sequenced the exon and promoter region of UBE2B in
patients with IA. The Chr5.133706925 A >G promoter
variant, located at the SP1-binding sites, was found in 32
of the 776 patients but was absent in 709 fertile men.
However, because only the promoter, exons and flanking
regions, which are adjacent to the 5' end and 3' end of the
gene but not transcribed into RNA, of UBE2B gene were
sequenced, it remains to be determined whether there are
disease-associated variants at intronic splice junctions.
In mammalian spermatogenesis, the histone post-
translational modifications such as acetylation, methylation,
Fig. 2 Evolutionary conservation of the promoter sequence of UBE2B affected by variants that are not seen in the controls. Multiple nucleic acid
alignments were performed with MegAlign (Demonstration System DNASTAR, Inc.). The identification numbers of the UBE2B promoter were as
follows: Human (NCBI ID: 7320), Rhesus (NCBI ID: 710678), Pig (NCBI ID: 100513527), Rabbit (NCBI ID: 100009132), mouse (NCBI ID: 22210) and
zebrafish (NCBI ID: 437020). The variant alleles are boxed
Fig. 3 Transactivation of WT and three UBE2B mutant promoters by
SP1. The pCMV-SP1 and the WT or mutant forms of the UBE2B promoter
that were cotransfected into HeLa, 293FT and TM4 cells. UBE2B
promoter activity was analyzed using luciferase assay. Compared
with WT and other mutants, SP1 failed to activate the UBE2B
Chr5.133706925 A > G promoter. The NC: pCMV empty vector was
cotransfected with the WT UBE2B promoter. Fold induction is shown
as the ratio of WT or mutants to the average of NC. (* P < 0.01)
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phosphorylation, sumoylation and ubiquitination have been
linked to the regulation of cellular activities such as gene
transcription, repair, replication and silencing [23, 24].
UBE2B protein, an ubiquitin-conjugating enzyme, can me-
diate H2A and H2B ubiquitylation and function during
transcription in somatic cells as well as germ cells [25–27].
UBE2B is mainly expressed in round spermatids and Sertoli
cells, and it is essential for normal spermatogenesis. Ube2b-
deficient male mice are infertile as a result of low numbers
of predominantly abnormal spermatozoa, abnormal sperm-
atid nuclear condensation, and sperm periaxonemal anom-
alies [16, 17, 28]. Furthermore, detailed analysis has shown
that UBE2B is responsible for proper chromosome cross-
over in the meiotic recombination of mouse spermato-
cytes, whereas UBE2B defects lead to arrest of the meiotic
prophase and abnormal chromosome synapsis [16, 17, 28].
These results clearly demonstrate the important role of
UBE2B in maintaining normal spermatogenesis and the in-
volvement of UBE2B defects in spermatogenic failure.
Therefore, it is reasonable to suggest that Chr5.133706925
A >G in the UBE2B promoter may affect gene expression
by altering the binding sites of some transcription factors,
which in turn results in spermatogenic defects.
To provide additional evidence for our conclusion, we
performed further experiments to address the biological
functional bases underlying the association between
UBE2B promoter variants and IA risk. First, the sequence
region around Chr5.133706925 (A >G) was predicted to
be a DNA-binding site of SP1, with the allele A to allele G
change leading to the alteration and possibly loss of func-
tion for this site. Second, the luciferase assay results
showed that substitution of A by G at Chr5.133706925
reduced the regulation of SP1 to the UBE2B promoter.
In this study, a biopsy of a patient (No. 188) with the
UBE2B Chr5.133706925 A > G confirmed the diagnosis
of non-obstructive azoospermia and further histopath-
ology showed abnormal spermatogenesis. Therefore,
these results collectively indicate that Chr5.133706925
A >G in UBE2B promoter confers susceptibility to IA. It
is possible that abrogation of the SP1 binding site due to
the presence of Chr5.133706925 (A > G) decreased the ex-
pression of UBE2B and thus led to spermatogenic failure.
Studies have identified several alternatively spliced
transcripts encoding SP1 isoforms that display stage and
cell-type-specific expression profiles in differentiating
germ cells of the seminiferous epithelium in the testis
[29]. Further studies need to be performed to confirm
that the GC box of Chr5.133706925 is actually bound by
SP1 in spermatids. Additional functional assays are
needed to confirm the effects of SP1 on transcription of
the UBE2B variant (Chr5.133706925 A > G) and examine
the results of the SP1 factor failure to bind in spermatids
with this variant.
Conclusions
In conclusion, with the use of bioinformatics analysis
and functional analysis, we identified a variant
(Chr5.133706925 A >G) that resides in the UBE2B gene
promoter and confers a high risk for IA in a Chinese
population, possibly through modification of the DNA-
binding ability of SP1 and subsequent reduction in UBE2B
expression. Our study also demonstrated that systematic
analysis of the genetic variants in large cohorts of patients
in addition to subsequent functional assays may provide
new insights into the cause of IA in humans.
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a patient with obstructive azoospermia as the control. (Magnification: X200)
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